Privium Fund Management B.V. Autolus Therapeutics PLC Transaction History
Privium Fund Management B.V.
- $469 Million
- Q2 2025
A detailed history of Privium Fund Management B.V. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Privium Fund Management B.V. holds 294,142 shares of AUTL stock, worth $691,233. This represents 0.14% of its overall portfolio holdings.
Number of Shares
294,142
Previous 251,674
16.87%
Holding current value
$691,233
Previous $390,000
71.79%
% of portfolio
0.14%
Previous 0.1%
Shares
11 transactions
Others Institutions Holding AUTL
# of Institutions
98Shares Held
163MCall Options Held
0Put Options Held
88.3K-
Wellington Management Group LLP Boston, MA27.1MShares$63.7 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$48.1 Million0.14% of portfolio
-
Deep Track Capital, LP Greenwich, CT17.8MShares$41.9 Million0.97% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$39.1 Million98.24% of portfolio
-
Armistice Capital, LLC New York, NY11MShares$25.9 Million0.26% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $214M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...